

# Randomized Placeboâ€Controlled Clinical Trial of Lorca Diabetes Mellitus: The BLOOMâ€DM Study

Obesity

20, 1426-1436

DOI: [10.1038/oby.2012.66](https://doi.org/10.1038/oby.2012.66)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet. <i>Obesity</i> , 2010, 18, 2301-2310.	1.5	24
2	Pharmacotherapeutic Options for the Treatment of Patients with Obesity. <i>Journal of Pharmacy Technology</i> , 2012, 28, 211-218.	0.5	0
3	WEIGHT MANAGEMENT: New medications for weight loss. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 59-61.	0.1	0
4	Psychopharmacologic Treatment of Obesity and Eating Disorders in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2012, 21, 831-859.	1.0	8
5	Management of diabetes in primary care: individualisation of care. <i>Practical Diabetes</i> , 2012, 29, 331.	0.1	2
6	Lorcaserin approval in the United States: Paving the way?. <i>Endocrinología Y Nutrición: Organo De La Sociedad Española De Endocrinología Y Nutrición</i> , 2012, 59, 521-522.	0.8	3
7	Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 675-691.	21.5	174
8	Developing New Drugs for Diabetes and Cardiometabolic Disorders. <i>Drugs</i> , 2012, 72, 1709-1711.	4.9	9
9	The leaf and seed aqueous extract of <i>Phyllanthus amarus</i> improves insulin resistance diabetes in experimental animal studies. <i>Journal of Ethnopharmacology</i> , 2012, 144, 705-711.	2.0	36
10	Lorcaserin approval in the United States: Paving the way?. <i>Endocrinología Y Nutrición (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlock	0.5	1
11	Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. <i>CardioRenal Medicine</i> , 2012, 2, 314-327.	0.7	20
12	Weight-loss drug wins US approval. <i>Nature</i> , 2012, , .	13.7	1
13	Lorcaserin Hydrochloride. <i>Hospital Pharmacy</i> , 2012, 47, 871-879.	0.4	0
14	Evaluation of lorcaserin for the treatment of obesity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1053-1059.	1.5	10
15	The central question of type 2 diabetes. <i>Pharmaceutical Patent Analyst</i> , 2013, 2, 399-427.	0.4	1
16	The unrelenting fall of the pharmacological treatment of obesity. <i>Endocrine</i> , 2013, 44, 598-609.	1.1	27
17	Pharmacologic Treatment Options for Obesity: What Is Old Is New Again. <i>Current Hypertension Reports</i> , 2013, 15, 182-189.	1.5	34
18	The Microbiome as a Therapeutic Target for Metabolic Diseases. <i>Drug Development Research</i> , 2013, 74, 376-384.	1.4	1

#	ARTICLE	IF	CITATIONS
19	A long journey to effective obesity treatments: is there light at the end of the tunnel?. <i>Experimental Biology and Medicine</i> , 2013, 238, 491-501.	1.1	10
20	New Obesity Agents: Lorcaserin and Phentermine/Topiramate. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1007-1016.	0.9	62
21	Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. <i>Current Medical Research and Opinion</i> , 2013, 29, 839-848.	0.9	23
22	Diabetes Modifies Effect of High-Phosphate Diet on Fibroblast Growth Factor-23 in Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1901-E1908.	1.8	18
23	Mechanisms underlying current and future anti-obesity drugs. <i>Trends in Neurosciences</i> , 2013, 36, 133-140.	4.2	90
24	New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 508-518.	1.2	45
25	American Association of Clinical Endocrinologistsâ€™™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
26	Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?. <i>Drugs</i> , 2013, 73, 1649-1651.	4.9	6
27	Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2013, 7, 304-383.	0.6	346
28	Lorcaserin and Phentermine/Topiramate: Two Leaps Forward in Weight Loss Pharmacotherapy. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1740-1740.	0.9	0
29	Milk protein hydrolysates activate 5-HT <sub>2C</sub> serotonin receptors: influence of the starting substrate and isolation of bioactive fractions. <i>Food and Function</i> , 2013, 4, 728.	2.1	15
30	Antiobesity Pharmacotherapy: New Drugs and Emerging Targets. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 53-66.	2.3	147
31	Lorcaserin for Weight Loss: Insights Into US Food and Drug Administration Approval. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013, 113, 25-30.	0.4	16
32	Pathophysiology of Human Visceral Obesity: An Update. <i>Physiological Reviews</i> , 2013, 93, 359-404.	13.1	1,751
33	Pharmacotherapy for childhood obesity: present and future prospects. <i>International Journal of Obesity</i> , 2013, 37, 1-15.	1.6	63
34	Therapy of obese patients with cardiovascular disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 200-204.	1.7	11
35	Gastrointestinal weight-loss surgery: glimpses at the molecular level. <i>Drug Discovery Today</i> , 2013, 18, 625-636.	3.2	5
36	Systemic administration of 5-HT <sub>2C</sub> receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 108, 8-15.	1.3	26

#	ARTICLE	IF	CITATIONS
37	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary. <i>Endocrine Practice</i> , 2013, 19, 536-557.	1.1	230
38	Obesity: A Focus on Pharmacotherapy. <i>Journal for Nurse Practitioners</i> , 2013, 9, 387-395.	0.4	1
39	Treating the obese diabetic. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 171-183.	1.3	9
40	Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (<sc>RCTs</sc>) and narrative review on short-term <sc>RCTs</sc>. <i>Obesity Reviews</i> , 2013, 14, 383-392.	3.1	117
41	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. <i>Drugs</i> , 2013, 73, 1-14.	4.9	139
42	Update on Treatment Strategies for Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1299-1306.	1.8	71
43	New and Emerging Pharmacologic Therapies for Type 2 Diabetes, Dyslipidemia, and Obesity. <i>Clinical Therapeutics</i> , 2013, 35, A3-A17.	1.1	26
44	Mitochondrial Fatty Acid Oxidation in Obesity. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 269-284.	2.5	175
45	New pharmacological approaches for obesity management. <i>Nature Reviews Endocrinology</i> , 2013, 9, 467-478.	4.3	47
46	Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs. <i>Pharmacotherapy</i> , 2013, 33, 1308-1321.	1.2	16
47	Effects of Transoral Gastroplasty on Glucose Homeostasis in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1901-1910.	1.8	5
48	Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin?. <i>Drugs</i> , 2013, 73, 393-395.	4.9	10
49	Lorcaserin: A Review of its Use in Chronic Weight Management. <i>Drugs</i> , 2013, 73, 463-473.	4.9	27
50	Safety of antiobesity drugs. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 171-181.	1.0	120
51	Lorcaserin: a guide to its use in chronic weight management. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 303-308.	0.3	0
52	Pharmacotherapy of Obesity: Clinical Treatments and Considerations. <i>American Journal of the Medical Sciences</i> , 2013, 345, 284-288.	0.4	184
53	Modulating the Human Gut Microbiome as an Emerging Therapeutic Paradigm. <i>Science Progress</i> , 2013, 96, 224-236.	1.0	17
54	Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 560-567.	1.3	63

#	ARTICLE	IF	CITATIONS
55	New medications for obesity management. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 407-411.	1.2	12
56	The Safety and Efficacy of Lorcaserin in the Management of Obesity. <i>Postgraduate Medicine</i> , 2013, 125, 62-72.	0.9	10
57	Lorcaserin. <i>Practical Diabetes</i> , 2013, 30, 136-137.	0.1	0
58	Obesity consultsâ€™ comprehensive obesity management in 2013: Understanding the shifting paradigm. <i>Obesity</i> , 2013, 21, S3-13; quiz S14-5.	1.5	4
59	Drug updates and approvals. <i>Nurse Practitioner</i> , 2013, 38, 24-42.	0.2	10
60	Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtypeâ€™targeted drugs. <i>Journal of Clinical Investigation</i> , 2013, 123, 4986-4991.	3.9	100
61	New Tools for Weight-Loss Therapy Enable a More Robust Medical Model for Obesity Treatment: Rationale for a Complications-Centric Approach. <i>Endocrine Practice</i> , 2013, 19, 864-874.	1.1	63
62	Application of Palladium-Mediated 18F-Fluorination to PET Radiotracer Development: Overcoming Hurdles to Translation. <i>PLoS ONE</i> , 2013, 8, e59187.	1.1	87
63	Lorcaserin for weight management. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 209.	1.1	17
64	Mental Function and Obesity. , 2013, , .		3
65	Pharmacotherapy for Obesity. <i>Journal of Menopausal Medicine</i> , 2014, 20, 90.	0.3	32
66	Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 173.	0.9	58
67	Obesity: Pathophysiology and Intervention. <i>Nutrients</i> , 2014, 6, 5153-5183.	1.7	120
68	Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2014, 3, 595-613.	1.0	11
69	Antiobesity Pharmacotherapy for Patients with Type 2 Diabetes: Focus on Long-Term Management. <i>Endocrinology and Metabolism</i> , 2014, 29, 410.	1.3	16
70	American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action. <i>Endocrine Practice</i> , 2014, 20, 956-976.	1.1	33
71	Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 809-822.	0.9	23
72	Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. <i>International Journal of Obesity</i> , 2014, 38, 325-333.	1.6	53

#	ARTICLE	IF	CITATIONS
73	Obesity Management: Applying Clinical Trial Data to Clinical Care. <i>Endocrine Practice</i> , 2014, 20, 6-19.	1.1	2
74	Weighing up the evidence: a meta-analysis and therapeutic audit of the treatments for obesity. <i>Bioscience Horizons</i> , 2014, 7, hzu003-hzu003.	0.6	1
75	Lorcaserin: A novel antiobesity drug. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2014, 5, 175-178.	0.2	45
76	Bariatric Endocrinology: Principles of Medical Practice. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-12.	0.6	14
77	A critical review of the treatment options available for obstructive sleep apnoea: an overview of the current literature available on treatment methods for obstructive sleep apnoea and future research directions. <i>Bioscience Horizons</i> , 2014, 7, hzu011-hzu011.	0.6	1
78	Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials. <i>Postgraduate Medicine</i> , 2014, 126, 7-18.	0.9	61
79	New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy. <i>Current Medical Research and Opinion</i> , 2014, 30, 961-969.	0.9	4
80	Update on obesity pharmacotherapy. <i>Annals of the New York Academy of Sciences</i> , 2014, 1311, 1-13.	1.8	74
81	Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release. <i>Diabetes Care</i> , 2014, 37, 3309-3316.	4.3	115
82	Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit. <i>Clinical Cardiology</i> , 2014, 37, 693-699.	0.7	31
83	Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight loss outcomes. <i>Obesity</i> , 2014, 22, 2137-2146.	1.5	44
84	New Antiobesity Agents. <i>Cardiology in Review</i> , 2014, 22, 43-50.	0.6	10
85	Pharmacotherapy Considerations in Diabetes and Obesity: Setting Patients up for Success. <i>Postgraduate Medicine</i> , 2014, 126, 100-109.	0.9	4
86	Past and future corollaries of theories on causes of metabolic syndrome and obesity related co-morbidities part 2: a composite unifying theory review of human-specific co-adaptations to brain energy consumption. <i>Archives of Public Health</i> , 2014, 72, 31.	1.0	7
87	Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 911-922.	5.5	155
88	New and Emerging Drug Molecules Against Obesity. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 65-76.	1.0	55
89	On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination. <i>Psychopharmacology</i> , 2014, 231, 787-800.	1.5	15
90	Obesity and Cardiovascular Disease. , 2014, , 285-294.		0

#	ARTICLE	IF	CITATIONS
91	New Pharmacological Treatments for the Management of Obesity. <i>Current Gastroenterology Reports</i> , 2014, 16, 394.	1.1	27
92	Pharmacotherapy for obesity: novel agents and paradigms. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 135-148.	1.1	78
93	Pharmacotherapy for Obesity. , 2014, , 261-277.		0
94	Long-term Drug Treatment for Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 74.	3.8	697
95	Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. <i>Current Medical Research and Opinion</i> , 2014, 30, 163-175.	0.9	145
96	The importance of weight management in type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2014, 68, 682-691.	0.8	209
97	Novel Agents for the Treatment of Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2014, 27, 100-112.	0.4	56
98	Managing Overweight and Obesity in Adults to Reduce Cardiovascular Disease Risk. <i>Current Atherosclerosis Reports</i> , 2014, 16, 445.	2.0	46
99	Tolerability and Safety of the New Anti-Obesity Medications. <i>Drug Safety</i> , 2014, 37, 693-702.	1.4	69
100	Meta-analysis and cost-effectiveness analysis of commercial weight loss strategies. <i>Obesity</i> , 2014, 22, 1942-1951.	1.5	138
101	Medical treatment of obesity: The past, the present and the future. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 665-684.	1.0	70
102	An evolving scientific basis for the prevention and treatment of pediatric obesity. <i>International Journal of Obesity</i> , 2014, 38, 887-905.	1.6	96
103	Anti-Obesity Agents and the US Food and Drug Administration. <i>Current Obesity Reports</i> , 2014, 3, 361-367.	3.5	0
104	Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 475-484.	0.7	7
105	Pharmacotherapy for weight loss. <i>BMJ, The</i> , 2014, 348, g3526-g3526.	3.0	9
106	Milk protein-derived peptides induce 5-HT <sub>2C</sub> -mediated satiety in vivo. <i>International Dairy Journal</i> , 2014, 38, 55-64.	1.5	15
107	Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 141-151.	5.5	31
109	Management of obesity and cardiometabolic risk &ndash; role of phentermine/extended release topiramate. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 35.	1.1	17

#	ARTICLE	IF	CITATIONS
110	Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults. <i>Obesity</i> , 2014, 22, S41-410.	1.5	155
111	Current and emerging medications for overweight or obesity in people with comorbidities. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1021-1032.	2.2	58
112	Characterization of the 5-HT <sub>2C</sub> receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00084.	1.1	25
114	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€” 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	1.1	443
115	Depression Worsening Associated With Lorcaserin. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 747-749.	0.7	4
116	Obesity medications. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 360-366.	1.2	15
117	Meta-chlorophenylpiperazine enhances leptin sensitivity in diet-induced obese mice. <i>British Journal of Pharmacology</i> , 2015, 172, 3510-3521.	2.7	12
118	Anti-obesity drugs. <i>Current Opinion in Lipidology</i> , 2015, 26, 536-543.	1.2	23
119	New and emerging drugs for the treatment of obesity. <i>Journal of the Korean Medical Association</i> , 2015, 58, 452.	0.1	0
120	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 1403-1414.	1.1	22
121	Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. <i>World Journal of Diabetes</i> , 2015, 6, 1246.	1.3	718
122	Recent Advances for Anti-Obesity Agents. <i>Journal of Korean Diabetes</i> , 2015, 16, 260.	0.1	1
123	Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. <i>Diabetes Care</i> , 2015, 38, 1161-1172.	4.3	170
124	Serotonin, a possible intermediate between disturbed circadian rhythms and metabolic disease. <i>Neuroscience</i> , 2015, 301, 155-167.	1.1	42
125	Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. <i>Current Medical Research and Opinion</i> , 2015, 31, 643-665.	0.9	19
126	Physician knowledge about and perceptions of obesity management. <i>Obesity Research and Clinical Practice</i> , 2015, 9, 573-583.	0.8	52
127	3 Medical Management of Obesity. , 2015, , 15-38.		0
128	Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, S134-S141.	0.4	17



#	ARTICLE	IF	CITATIONS
129	Obesity Education Strategies for Cancer Prevention in Women's Health. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 249-258.	0.3	7
130	European Guidelines for Obesity Management in Adults. <i>Obesity Facts</i> , 2015, 8, 402-424.	1.6	2,172
131	New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects. <i>Canadian Journal of Cardiology</i> , 2015, 31, 142-152.	0.8	47
132	Drug treatment of obesity: Current status and future prospects. <i>European Journal of Internal Medicine</i> , 2015, 26, 89-94.	1.0	85
133	Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 305-315.	1.0	35
134	Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 342-362.	1.8	891
135	Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. <i>Diabetes</i> , 2015, 64, 2299-2309.	0.3	41
136	Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. <i>Current Obesity Reports</i> , 2015, 4, 287-302.	3.5	97
137	Therapeutic Potential of 5-HT <sub>2C</sub> Receptor Agonists for Addictive Disorders. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1071-1088.	1.7	75
138	Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes. <i>Endocrine Practice</i> , 2015, 21, 634-644.	1.1	9
139	Efficacy comparison of medications approved for chronic weight management. <i>Obesity</i> , 2015, 23, S4-7.	1.5	24
140	Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk. <i>Current Cardiology Reports</i> , 2015, 17, 35.	1.3	14
141	Health Benefits of Long-Term Weight-Loss Maintenance. <i>Annual Review of Nutrition</i> , 2015, 35, 475-516.	4.3	67
142	The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. <i>Drugs</i> , 2015, 75, 935-945.	4.9	46
143	Current and Emerging Treatment Options in Diabetes Care. <i>Handbook of Experimental Pharmacology</i> , 2015, 233, 437-459.	0.9	20
144	Neural Control of Energy Balance: Translating Circuits to Therapies. <i>Cell</i> , 2015, 161, 133-145.	13.5	204
145	Past and present of antiobesity agents: Focus on monoamine modulators. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 697-706.	0.5	16
146	Anti-hypertensive Drug Treatment of Patients with the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications. <i>Current Hypertension Reports</i> , 2015, 17, 558.	1.5	37

#	ARTICLE	IF	CITATIONS
147	Central Serotonergic Neurons Activate and Recruit Thermogenic Brown and Beige Fat and Regulate Glucose and Lipid Homeostasis. <i>Cell Metabolism</i> , 2015, 21, 692-705.	7.2	70
148	Treatment of Obesity in 2015. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2015, 35, 81-92.	1.2	42
149	Medications for weight loss. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 91-97.	1.2	24
150	Interventions of Weight Reduction and Prevention in Children and Adolescents. <i>American Journal of Therapeutics</i> , 2015, 22, 159-166.	0.5	0
151	Ghrelin's Orexigenic Effect Is Modulated via a Serotonin 2C Receptor Interaction. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1186-1197.	1.7	98
152	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. <i>Postgraduate Medicine</i> , 2015, 127, 480-493.	0.9	9
153	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2015, 38, 1567-1582.	4.3	180
154	5-Hydroxytryptamine Medications for the Treatment of Obesity. <i>Journal of Neuroendocrinology</i> , 2015, 27, 389-398.	1.2	70
155	Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity. <i>RSC Advances</i> , 2015, 5, 86954-86966.	1.7	32
156	Pharmacotherapy for the management of obesity. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1376-1385.	1.5	94
157	Clinical Management of Type 2 Diabetes Mellitus after Bariatric Surgery. <i>Current Atherosclerosis Reports</i> , 2015, 17, 59.	2.0	5
158	Pharmacotherapy for the treatment of obesity. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 173-183.	1.6	24
159	Lorcaserin Hcl for the treatment of obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2531-2538.	0.9	25
160	Pharmacological Management of Obesity in Pediatric Patients. <i>Annals of Pharmacotherapy</i> , 2015, 49, 220-232.	0.9	41
161	Pharmacological Management of the Obese Patient. <i>American Journal of Lifestyle Medicine</i> , 2015, 9, 137-156.	0.8	0
162	Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-15.	0.6	130
164	Evidence for the Association of a Deleted Variant in the 5'-Flanking Region of the Chicken serotonin transporter (5-HTT) Gene with a Temporary Increase in Feed Intake and Growth Rate. <i>Animals</i> , 2016, 6, 63.	1.0	6
165	Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial. <i>Diabetes</i> , 2016, 65, 2943-2953.	0.3	49

#	ARTICLE	IF	CITATIONS
166	Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOMâ€œDM studies. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 945-948.	2.2	10
167	Long-term effects of weight-reducing drugs in people with hypertension. <i>The Cochrane Library</i> , 2016, 3, CD007654.	1.5	48
168	Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. <i>BMC Medicine</i> , 2016, 14, 191.	2.3	113
169	Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adultsâ€œRandomized Controlled Trial. <i>EBioMedicine</i> , 2016, 13, 190-200.	2.7	108
170	Khat (<i>Catha edulis</i>) and Obesity: A Scoping Review of Animal and Human Studies. <i>Annals of Nutrition and Metabolism</i> , 2016, 69, 200-211.	1.0	24
171	American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. <i>Endocrine Practice</i> , 2016, 22, 1-203.	1.1	952
172	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm â€œ 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	1.1	405
173	Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. <i>Clinical Therapeutics</i> , 2016, 38, 1498-1509.	1.1	7
174	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. <i>Current Atherosclerosis Reports</i> , 2016, 18, 36.	2.0	13
175	The future of the Roux-en-Y gastric bypass. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 777-784.	1.4	15
176	Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. <i>Postgraduate Medicine</i> , 2016, 128, 364-370.	0.9	19
178	Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and <sc>SGLT</sc>2s. <i>Obesity</i> , 2016, 24, 1955-1961.	1.5	91
179	Current drugs for weight loss. <i>Practical Diabetes</i> , 2016, 33, 229-232.	0.1	0
180	An update on naltrexone/bupropion extended-release in the treatment of obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2235-2242.	0.9	10
181	Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet. <i>Clinical Therapeutics</i> , 2016, 38, 2227-2238.e4.	1.1	11
182	Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings. <i>Advances in Therapy</i> , 2016, 33, 1853-1866.	1.3	73
183	Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with â‰¥5% weight loss. <i>Postgraduate Medicine</i> , 2016, 128, 740-746.	0.9	2
184	Pharmacotherapy for Obesity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 521-538.	1.2	28

#	ARTICLE	IF	CITATIONS
185	Drugs to treat obesity: do they work?. Postgraduate Medical Journal, 2016, 92, 401-406.	0.9	11
186	Type 2 Diabetes Treatment in the Patient with Obesity. Endocrinology and Metabolism Clinics of North America, 2016, 45, 553-564.	1.2	7
187	Weight maintenance: challenges, tools and strategies for primary care physicians. Obesity Reviews, 2016, 17, 81-93.	3.1	72
188	Pharmacological management of obesity in patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 415-423.	1.2	0
189	Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss. Diabetes Care, 2016, 39, 2108-2110.	4.3	12
190	Safety and tolerability review of lorcaserin in clinical trials. Clinical Obesity, 2016, 6, 285-295.	1.1	30
191	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. Cardiovascular Diabetology, 2016, 15, 95.	2.7	52
192	Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. Diabetes Care, 2016, 39, S260-S267.	4.3	37
193	Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgraduate Medicine, 2016, 128, 591-597.	0.9	10
194	Combination Varenicline and Lorcaserin for Tobacco Dependence Treatment and Weight Gain Prevention in Overweight and Obese Smokers: A Pilot Study. Nicotine and Tobacco Research, 2016, 19, ntw304.	1.4	17
195	Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity, 2016, 24, 2269-2277.	1.5	44
196	Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial. Nicotine and Tobacco Research, 2016, 19, ntw301.	1.4	39
197	A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss. BMC Obesity, 2016, 3, 42.	3.1	11
198	Importancia del peso en el control del paciente con diabetes mellitus tipo 2: hacia una visi3n adipoc3ntrica del abordaje de la diabetes. Medicina Cl3nica, 2016, 147, 8-16.	0.3	4
199	The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. Psychopharmacology, 2016, 233, 417-424.	1.5	21
200	Obesity and diabetes mellitus in the Arab world. Journal of Taibah University Medical Sciences, 2016, 11, 301-309.	0.5	24
201	Role of Bupropion Plus Naltrexone for the Management of Obesity. Journal of Pharmacy Technology, 2016, 32, 125-132.	0.5	4
202	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events. JAMA - Journal of the American Medical Association, 2016, 315, 2424.	3.8	614

#	ARTICLE	IF	CITATIONS
203	Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 357-371.	2.2	12
204	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2016, , 797-809.		0
205	Fatty acid metabolism and the basis of brown adipose tissue function. <i>Adipocyte</i> , 2016, 5, 98-118.	1.3	103
206	Lifestyle Therapy for Diabetes Mellitus. , 2016, , 221-243.		3
207	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. <i>Postgraduate Medicine</i> , 2016, 128, 371-380.	0.9	55
208	Medical Approaches to Weight-Centric Management of Obese Patients with Type 2 Diabetes. , 2016, , 47-59.		1
209	A Comparison of New Pharmacological Agents for the Treatment of Obesity. <i>Annals of Pharmacotherapy</i> , 2016, 50, 376-388.	0.9	18
210	Management of obesity. <i>Lancet, The</i> , 2016, 387, 1947-1956.	6.3	715
211	Pharmacological Management. , 2016, , 45-51.		0
212	Obesity context of type 2 diabetes and medication perspectives. <i>Apollo Medicine</i> , 2016, 13, 91-96.	0.0	2
213	Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. <i>Future Cardiology</i> , 2016, 12, 129-138.	0.5	31
214	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 92-107.	1.1	35
215	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 52-63.	1.0	4
216	Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 891-897.	1.2	21
217	Current and Future Medical Treatment of Obesity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2017, 27, 181-190.	0.6	5
218	TrpC5 Mediates Acute Leptin and Serotonin Effects via Pomc Neurons. <i>Cell Reports</i> , 2017, 18, 583-592.	2.9	75
219	Practical Use of Pharmacotherapy for Obesity. <i>Gastroenterology</i> , 2017, 152, 1765-1779.	0.6	49
220	Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment. <i>Clinical Therapeutics</i> , 2017, 39, 837-848.e7.	1.1	6

#	ARTICLE	IF	CITATIONS
221	Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1295-1305.	2.2	111
222	Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1655-1668.	2.2	83
223	Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?. <i>Acta Diabetologica</i> , 2017, 54, 715-725.	1.2	18
224	Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. <i>Obesity</i> , 2017, 25, 857-865.	1.5	38
225	Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years. <i>New England Journal of Medicine</i> , 2017, 376, 1995-1997.	13.9	29
226	Epidemiology of Obesity and Pharmacologic Treatment Options. <i>Nutrition in Clinical Practice</i> , 2017, 32, 441-462.	1.1	21
227	Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 891-896.	1.5	5
228	Current and cutting-edge interventions for the treatment of obese patients. <i>European Journal of Radiology</i> , 2017, 93, 134-142.	1.2	23
229	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. <i>Current Diabetes Reports</i> , 2017, 17, 34.	1.7	36
230	Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus. <i>Obesity</i> , 2017, 25, 842-849.	1.5	16
231	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
232	Pharmacotherapy for Weight Management in the VHA. <i>Journal of General Internal Medicine</i> , 2017, 32, 70-73.	1.3	19
233	5-HT <sub>2C</sub> Agonists Modulate Schizophrenia-Like Behaviors in Mice. <i>Neuropsychopharmacology</i> , 2017, 42, 2163-2177.	2.8	42
234	Nutrition Therapy for the Prevention and Treatment of Prediabetes and Diabetes. , 2017, , 151-171.		0
235	Role of impulsivity and reward in the anti-obesity actions of 5-HT <sub>2C</sub> receptor agonists. <i>Journal of Psychopharmacology</i> , 2017, 31, 1403-1418.	2.0	30
236	The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement. <i>Current Atherosclerosis Reports</i> , 2017, 19, 45.	2.0	8
237	Pasado, presente y futuro de la farmacoterapia para la obesidad. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 256-264.	0.4	3
238	Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness. <i>Obesity Surgery</i> , 2017, 27, 3281-3291.	1.1	18

#	ARTICLE	IF	CITATIONS
239	Weight Management in Patients with Type 1 Diabetes and Obesity. <i>Current Diabetes Reports</i> , 2017, 17, 92.	1.7	87
240	Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 303-313.	1.2	5
241	Current and emerging pharmacotherapies for obesity in Australia. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 501-521.	0.8	9
242	Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?. <i>Clinical Obesity</i> , 2017, 7, 347-353.	1.1	6
243	Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity. <i>Clinical Obesity</i> , 2017, 7, 337-346.	1.1	8
244	Lorcaserin improves glycemic control via a melanocortin neurocircuit. <i>Molecular Metabolism</i> , 2017, 6, 1092-1102.	3.0	40
246	Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, 197-205.	0.4	79
248	Past, present and future of pharmacotherapy for obesity. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 256-264.	0.1	4
249	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. <i>Pharmaceutical Medicine</i> , 2017, 31, 399-421.	1.0	3
250	The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0mg. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 44.	1.2	37
251	Obesity: Current and potential pharmacotherapeutics and targets. , 2017, 170, 116-147.		145
252	Care of the Obese Patient. , 2017, , 699-707.		0
253	Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials. <i>Obesity</i> , 2017, 25, 39-44.	1.5	13
254	Review of multimodal therapies for obesity treatment: Including dietary, counseling strategies, and pharmacologic interventions. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 12-17.	0.3	10
255	Management of Obesity in Patients with Diabetes Mellitus. <i>Journal of Korean Diabetes</i> , 2017, 18, 229.	0.1	1
256	Weight loss medications in Canada &nbsp;&nbsp;&nbsp;a new frontier or a repeat of past mistakes?. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 413-417.	1.1	9
257	Cardiometabolic Effects of Anti-obesity Pharmacotherapy. <i>Current Atherosclerosis Reports</i> , 2018, 20, 18.	2.0	7
258	Select medications that unexpectedly lower HbA1c levels. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 587-590.	0.7	0

#	ARTICLE	IF	CITATIONS
259	Short- and Long-Term Changes in Health-Related Quality of Life with Weight Loss: Results from a Randomized Controlled Trial. <i>Obesity</i> , 2018, 26, 985-991.	1.5	21
260	Medically Supervised Weight Loss Programs. , 2018, , 211-223.		0
261	Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population*. <i>Military Medicine</i> , 2018, 183, 45-50.	0.4	3
262	Safety and tolerability of new-generation anti-obesity medications: a narrative review. <i>Postgraduate Medicine</i> , 2018, 130, 173-182.	0.9	90
263	Pharmacotherapy for obesity in individuals with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 223-231.	0.9	15
264	Updates on obesity pharmacotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1411, 106-119.	1.8	65
265	The safety of pharmacologic treatment for pediatric obesity. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 379-385.	1.0	32
266	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2018, 26, 513-521.	1.5	4
267	A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet. <i>Obesity</i> , 2018, 26, 299-309.	1.5	20
268	Obesity. <i>Journal of the American College of Cardiology</i> , 2018, 71, 69-84.	1.2	375
269	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1309-1319.e7.	0.6	56
270	Pediatric obesity: Current concepts. <i>Disease-a-Month</i> , 2018, 64, 98-156.	0.4	48
271	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patientsâ€”Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , 2018, 202, 39-48.	1.2	15
272	The Science of Obesity Management: An Endocrine Society Scientific Statement. <i>Endocrine Reviews</i> , 2018, 39, 79-132.	8.9	522
273	Medication use for the treatment of diabetes in obese individuals. <i>Diabetologia</i> , 2018, 61, 265-272.	2.9	35
274	Current pharmacotherapy for obesity. <i>Nature Reviews Endocrinology</i> , 2018, 14, 12-24.	4.3	287
275	Progress and challenges in anti-obesity pharmacotherapy. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 237-248.	5.5	210
276	7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetesâ€”2018. <i>Diabetes Care</i> , 2018, 41, S65-S72.	4.3	111



#	ARTICLE	IF	CITATIONS
277	Obesity Pharmacotherapy. <i>Medical Clinics of North America</i> , 2018, 102, 135-148.	1.1	98
278	Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration. <i>Pharmacotherapy</i> , 2018, 38, 19-28.	1.2	22
279	Drug Treatment of Obesity: From Bench to Bedside. , 2018, , .		0
280	Lorcaserin and metabolic disease: weight loss dependent and independent effects. <i>Obesity Science and Practice</i> , 2018, 4, 499-505.	1.0	5
281	Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1915-1926.	0.9	8
282	Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 469-478.	1.1	7
283	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 2269-2279.	6.3	70
284	The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e70-e87.	2.5	136
285	A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion and stress related eating, food cravings and appetite. <i>Clinical Obesity</i> , 2018, 8, 383-390.	1.1	11
286	Peptide based multiagonists: a new paradigm in metabolic pharmacology. <i>Journal of Internal Medicine</i> , 2018, 284, 581-602.	2.7	40
287	Addressing Obesity in Clinical Gynecology Practice. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 10-26.	0.6	5
288	Serotonin 5-HT <sub>2C</sub> Receptor Activation Suppresses Binge Intake and the Reinforcing and Motivational Properties of High-Fat Food. <i>Frontiers in Pharmacology</i> , 2018, 9, 821.	1.6	17
289	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. <i>Current Atherosclerosis Reports</i> , 2018, 20, 39.	2.0	20
290	Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 465-471.	0.8	6
291	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
292	Centrally Acting Agents for Obesity: Past, Present, and Future. <i>Drugs</i> , 2018, 78, 1113-1132.	4.9	90
293	Persistence of newer anti-obesity medications in a real-world setting. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 348-356.	1.1	36
294	Lorcaserin – Elixir or Liability?. <i>New England Journal of Medicine</i> , 2018, 379, 1174-1175.	13.9	2

#	ARTICLE	IF	CITATIONS
295	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	13.9	205
296	Treatment: New Drugs. , 2019, , 464-472.		0
297	Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. <i>Korean Journal of Family Medicine</i> , 2019, 40, 63-71.	0.4	13
298	Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): a combined subgroup analysis from three randomized, controlled clinical trials. <i>Obesity Science and Practice</i> , 2019, 5, 238-245.	1.0	4
299	Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e029426.	0.8	1
300	Safety and Efficacy of Weight Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy. <i>Pharmacotherapy</i> , 2019, 39, 1204-1215.	1.2	10
301	Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes. <i>Annals of Medicine and Surgery</i> , 2019, 45, 75-81.	0.5	12
302	Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	1.4	23
303	Ligand-directed serotonin 5-HT <sub>2C</sub> receptor desensitization and sensitization. <i>European Journal of Pharmacology</i> , 2019, 848, 131-139.	1.7	8
304	Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. <i>Metabolomics</i> , 2019, 15, 93.	1.4	150
305	Pharmaceutical approaches to weight management: behavioural mechanisms of action. <i>Current Opinion in Physiology</i> , 2019, 12, 26-32.	0.9	2
306	Obesity an overview: Genetic conditions and recent developments in therapeutic interventions. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2112-2120.	1.8	11
307	Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies. <i>Obesity Science and Practice</i> , 2019, 5, 120-129.	1.0	4
308	Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule. <i>Endocrine Reviews</i> , 2019, 40, 1092-1107.	8.9	213
309	Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. , 2019, 198, 160-188.		81
310	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, vi-xi.	1.5	6
311	Nanotechnology-Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801184.	3.9	28
312	Pharmacotherapy of Obesity: Limits and Perspectives. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 349-364.	1.0	14

#	ARTICLE	IF	CITATIONS
313	Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1487-1492.	2.2	38
314	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	1.1	245
315	8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes 2019. <i>Diabetes Care</i> , 2019, 42, S81-S89.	4.3	136
316	Obesity and type 2 diabetes: Also linked in therapeutic options. <i>Endocrinología, Diabetes Y Nutrición (English Ed)</i> , 2019, 66, 140-149.	0.1	9
317	Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 140-149.	0.1	13
318	Neuropeptide receptors as potential pharmacological targets for obesity. , 2019, 196, 59-78.		13
319	Pharmacotherapy for Weight Management. , 2019, , 395-411.		4
320	Body Weight Considerations in the Management of Type 2 Diabetes. <i>Advances in Therapy</i> , 2019, 36, 44-58.	1.3	139
321	Medications Indicated for Chronic Weight Management. <i>Endocrinology</i> , 2019, , 401-424.	0.1	0
322	Pharmacologic Agents Chapter for Abdominal Obesity. , 2019, , 51-66.		1
323	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 170-192.	1.5	184
324	Evaluation and Treatment of Insulin Resistance and Hyperglycemic States. , 2019, , 235-250.		0
325	Choosing a Medication. , 2019, , 105-119.		0
326	Hypertension in Obesity: Novel Insights. <i>Current Hypertension Reviews</i> , 2020, 16, 30-36.	0.5	21
327	Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. , 2020, 205, 107417.		52
328	Low-level laser therapy for weight reduction: a randomized pilot study. <i>Lasers in Medical Science</i> , 2020, 35, 663-675.	1.0	13
329	An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 21-28.	0.9	9
330	Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 35-44.	0.7	4

#	ARTICLE	IF	CITATIONS
331	Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 183-190.	1.3	11
332	Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 53-64.	1.3	79
333	Bariatric Embolization. <i>Advances in Clinical Radiology</i> , 2020, 2, 101-112.	0.1	0
334	Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107730.	1.2	9
335	Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8985.	1.8	75
336	The risk of cardiovascular complications with current obesity drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1095-1104.	1.0	14
337	Peripheral and central serotonin in the regulation of glucose metabolism. <i>Handbook of Behavioral Neuroscience</i> , 2020, , 893-900.	0.7	1
338	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. <i>International Journal of Diabetes in Developing Countries</i> , 2020, 40, 1-122.	0.3	16
339	A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study. <i>Menopause</i> , 2020, 27, 1228-1235.	0.8	6
340	8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes 2020. <i>Diabetes Care</i> , 2020, 43, S89-S97.	4.3	126
341	Weight loss: Lifestyle interventions and Pharmacotherapy. , 2020, , 219-234.		1
342	Recent Advances in Transition-Metal-Catalyzed Oxidative Annulations to Benzazepines and Benzodiazepines. <i>Advanced Synthesis and Catalysis</i> , 2020, 362, 4861-4875.	2.1	30
343	Obesity Treatment. <i>Orthopaedic Nursing</i> , 2020, 39, 121-127.	0.2	3
344	Medications Available for Weight Reduction in Elective Total Joint Arthroplasty. <i>JBJS Reviews</i> , 2020, 8, e0123-e0123.	0.8	4
345	Medications for the treatment of obesity in adolescents. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882091878.	1.4	24
346	Global Mapping of Interventions to Improve Quality of Life of People with Diabetes in 1990-2018. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1597.	1.2	16
347	Angiogenesis in obesity. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 110103.	2.5	38
348	Role of the serotonergic system in appetite and ingestion control. <i>Handbook of Behavioral Neuroscience</i> , 2020, , 469-487.	0.7	3

#	ARTICLE	IF	CITATIONS
349	Legend of Weight Loss: a Crosstalk Between the Bariatric Surgery and the Brain. <i>Obesity Surgery</i> , 2020, 30, 1988-2002.	1.1	21
350	Impact of weight loss interventions on patient-reported outcomes in overweight and obese adults with type 2 diabetes: a systematic review. <i>Journal of Behavioral Medicine</i> , 2020, 43, 873-891.	1.1	7
351	Patient Perspectives on Obesity Management: Need for Greater Discussion of BMI and Weight-Loss Options Beyond Diet and Exercise, Especially in Patients With Diabetes. <i>Endocrine Practice</i> , 2020, 26, 471-483.	1.1	15
352	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
353	Palladium-Catalyzed [5 + 2] Heteroannulation of Phenethylamides with 1,3-Dienes to Dopaminergic 3-Benzazepines. <i>Organic Letters</i> , 2020, 22, 3591-3595.	2.4	12
354	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. <i>Nature Reviews Cardiology</i> , 2021, 18, 291-304.	6.1	141
355	Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. <i>Obesity Reviews</i> , 2021, 22, e13170.	3.1	19
356	Pathophysiology of Obesity and Cancer: Drugs and Signaling Targets. , 2021, , 43-63.		0
357	Obesity: Medical and Surgical Treatment. , 2021, , 131-175.		0
358	Long-term effects of weight-reducing drugs in people with hypertension. <i>The Cochrane Library</i> , 2021, 1, CD007654.	1.5	10
359	Efficacy and safety of glucagon-like peptide-1/glucagon receptor coagonist <a href="#">64565111</a> in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. <i>Clinical Obesity</i> , 2021, 11, e12433.	1.1	26
360	Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity. , 2021, , 125-148.		0
361	Pharmacologic Weight Loss: An Underutilized Practice in the Fight Against Obesity. <i>Interventions in Obesity &amp; Diabetes</i> , 2021, 4, .	0.0	0
362	Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. <i>World Journal of Men's Health</i> , 2021, 39, 208.	1.7	71
363	Embolizaç�o da art�ria g�strica esquerda como alternativa para supress�o de appetite e perda de peso em pacientes obesos: uma revis�o integrativa. <i>Research, Society and Development</i> , 2021, 10, e17110211629.	0.0	0
365	Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. <i>International Journal of Obesity</i> , 2021, 45, 1249-1258.	1.6	70
366	&lt;i&gt;Gamitaeumjowee-Tang&lt;/i&gt; for weight loss in diabetic patients: A retrospective chart review. <i>Journal of Korean Medicine</i> , 2021, 42, 46-58.	0.1	5
367	Role of serotonin in body weight, insulin secretion and glycaemic control. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12960.	1.2	20

#	ARTICLE	IF	CITATIONS
368	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1013-1025.	2.6	6
369	Improvement in mood symptoms after postbariatric surgery among people with obesity: A systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3458.	1.7	21
370	Barbadin potentiates long-term effects of lorcaserin on POMC neurons and weight loss. <i>Journal of Neuroscience</i> , 2021, 41, JN-RM-3210-20.	1.7	11
371	Central 5-HT <sub>2C</sub> in the Control of Metabolic Homeostasis. <i>Frontiers in Endocrinology</i> , 2021, 12, 694204.	1.5	7
372	High-Throughput Screening of Mouse Gene Knockouts Identifies Established and Novel High Body Fat Phenotypes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3753-3785.	1.1	8
373	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2587-2595.	1.1	7
374	Obesity Management in Cardiometabolic Disease: State of the Art. <i>Current Atherosclerosis Reports</i> , 2021, 23, 59.	2.0	16
375	Obesity—An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. <i>Biomolecules</i> , 2021, 11, 1426.	1.8	35
376	Association Between Obesity and Cardiovascular Disease in Elderly Patients With Diabetes: A Retrospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e515-e527.	1.8	17
377	Nanomaterials Based Electrochemical Sensors for Serotonin Detection: A Review. <i>Chemosensors</i> , 2021, 9, 14.	1.8	29
378	Mining Emerging Biomedical Literature for Understanding Disease Associations in Drug Discovery. <i>Methods in Molecular Biology</i> , 2014, 1159, 171-206.	0.4	9
379	Treatment of Obesity in Mitigating Metabolic Risk. <i>Circulation Research</i> , 2020, 126, 1646-1665.	2.0	36
380	Determinants of knowledge, attitude and practice in patients with both type 2 diabetes and chronic kidney disease in Fiji. <i>F1000Research</i> , 2019, 8, 239.	0.8	7
381	A review on the current drugs and new targets for obesity. <i>Journal of Applied Pharmaceutical Research</i> , 2020, 8, 11-21.	0.1	3
382	Dört aylık ve Yeme Arasındaki İlişki: Psikolojik ve Tıbbiyolojik Yaklaşımlar. <i>Current Approaches in Psychiatry</i> , 2018, 10, 1-1.	0.2	1
383	Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. <i>Annals of Translational Medicine</i> , 2019, 7, 393-393.	0.7	39
384	Current trends in the pharmacotherapy for obesity. <i>Endocrine Oncology and Metabolism</i> , 2016, 2, 50-59.	0.0	1
385	Current Options for the Pharmacotherapy of Obesity. <i>Current Pharmaceutical Design</i> , 2019, 25, 2019-2032.	0.9	5

#	ARTICLE	IF	CITATIONS
386	New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome. <i>Current Diabetes Reviews</i> , 2013, 9, 137-145.	0.6	77
387	Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1232-1243.	0.6	13
388	8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021. <i>Diabetes Care</i> , 2021, 44, S100-S110.	4.3	109
389	The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 541699.	1.5	4
390	Therapies for Obesity and Medication-Associated Weight Gain. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2013, 51, 13-16.	0.3	5
391	Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, S39-S46.	0.6	5
392	Pharmacotherapy for obesity: What you need to know. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 951-958.	0.6	28
393	Weight Loss Drugs Recently Approved by the FDA. <i>Journal of Korean Diabetes</i> , 2013, 14, 58.	0.1	3
394	The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. <i>Journal of Clinical Imaging Science</i> , 2015, 5, 32.	0.4	21
395	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. <i>Indian Journal of Endocrinology and Metabolism</i> , 2020, 24, 1.	0.2	85
396	Treating morbid obesity in cirrhosis: A quest of holy grail. <i>World Journal of Hepatology</i> , 2015, 7, 2819.	0.8	17
397	The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. <i>Journal of Obesity and Metabolic Syndrome</i> , 2019, 28, 158-166.	1.5	16
398	Current Long-Term Pharmacotherapies for the Management of Obesity. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020, 29, 99-109.	1.5	13
399	Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. <i>The Korean Journal of Obesity</i> , 2016, 25, 121-128.	0.2	2
401	Drug Therapy for Obesity. <i>The Korean Journal of Obesity</i> , 2012, 21, 197.	0.2	10
402	Was it worth the weight? - Drug review on two new weight loss agents: lorcaserin (Belviq®) and phentermine/topiramate ER (Qsymia™). <i>Mental Health Clinician</i> , 2012, 2, 144-151.	0.5	0
403	Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2013, 3, 178-190.	0.2	1
404	Bariatric Surgery in Treatment of the Obese Patient with Type 2 Diabetes. , 2014, , 521-529.		0

#	ARTICLE	IF	CITATIONS
405	Drugs for Weight Loss and Maintenance: Present and Future. , 2014, , 225-245.		0
406	Obesity, a burning problem. IOSR Journal of Pharmacy, 2014, 04, 01-05.	0.1	2
407	HIGH PREVALENCE OF GENERAL AND ABDOMINAL OBESITY AND RELATIONSHIP OF OBESITY WITH DIABETES MELLITUS IN PATIENTS WITH PSYCHIATRIC DISORDERS. Journal of Diabetes and Obesity, 2014, 1, 1-6.	0.2	0
408	Prescription Medications for the Treatment of Obesity. , 2015, , 261-270.		0
409	Care of the Obese Patient. , 2015, , 1-9.		0
410	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. Growth Hormone, 2015, , 91-109.	0.2	0
411	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2015, , 1-16.		0
412	Safety of Anti-Obesity Drugs Approved for Long-Term Use. The Korean Journal of Obesity, 2015, 24, 17-27.	0.2	7
413	New Drugs for Obesity Treatment. Korean Journal of Medicine, 2016, 90, 121-126.	0.1	1
414	Phentermine/Topiramate extended release versus Lorcaserin for weight reduction in obese adult patients: design of a randomized, double-blind, multicentric clinical study. , 2016, 2, .		0
415	Advances in Pharmacological Treatment of Pediatric Obesity. , 2016, , 333-351.		0
416	Individualizing Lifestyle Therapy for Patients with Obesity. Endocrine Practice, 2016, 22, 14-20.	1.1	0
417	Overview of Medical and Surgical Treatment of Severe Obesity. , 2017, , 75-82.		0
418	Medications Indicated for Chronic Weight Management. Endocrinology, 2017, , 1-24.	0.1	0
419	The role of anti-obesity drugs in the management of obese diabetics. Medicinski Glasnik Specijalne Bolnice Za Bolesti Åtitaste A½lezde I Bolesti Metabolizma Zlatibor, 2018, 23, 15-21.	0.1	0
421	Recent Advances in Anti-Obesity Agents. Korean Journal of Medicine, 2018, 93, 501-508.	0.1	10
422	Anti-Obesity Pharmacotherapy After Bariatric Surgery. , 2019, , 121-126.		0
423	Determinants of knowledge, attitude and practice in patients with both type 2 diabetes and chronic kidney disease in Fiji. F1000Research, 2019, 8, 239.	0.8	6



#	ARTICLE	IF	CITATIONS
424	Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss. <i>Current Drug Therapy</i> , 2019, 14, 74-78.	0.2	0
426	Mechanisms of action and clinical applications of anti-obesity drugs currently available in Korea. <i>Journal of the Korean Medical Association</i> , 2019, 62, 588-597.	0.1	2
427	Therapeutic Management of Obesity. <i>Contemporary Cardiology</i> , 2021, , 323-339.	0.0	1
428	Has the bloom gone out of lorcaserin following the CAMELLIA-TIMI61 trial?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 261-264.	0.9	4
429	Obesity and schizophrenia: New drugs, new hopes. <i>Psihijatrija Danas</i> , 2020, 52, 113-130.	0.1	0
430	Drugs for Weight Loss and Maintenance: Present and Future. , 2014, , 225-245.		0
431	Lorcaserin (Belviq): A Selective Serotonin 5-HT <sub>2C</sub> Agonist In the Treatment of Obesity. <i>P and T</i> , 2013, 38, 525-34.	1.0	26
432	New drug therapies for the treatment of overweight and obese patients. <i>American Health and Drug Benefits</i> , 2013, 6, 423-30.	0.5	9
433	Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2016, 33, 6-16.	0.6	1
434	Diet and Obesity-Induced Methylglyoxal Production and Links to Metabolic Disease. <i>Chemical Research in Toxicology</i> , 2021, 34, 2424-2440.	1.7	11
435	Drug Therapy of Childhood Obesity. <i>Journal of Nutrition &amp; Food Sciences</i> , 2018, 08, .	1.0	0
436	Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?. <i>CNS Drugs</i> , 2022, 36, 113-122.	2.7	9
437	Research Progresses for 5-Hydroxytryptamine in Lipid Metabolism. <i>Bioprocess</i> , 2022, 12, 1-9.	0.1	0
440	8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S113-S124.	4.3	128
442	Update of Indoles: Promising molecules for ameliorating metabolic diseases. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112957.	2.5	11
443	Update on pharmacology of obesity: benefits and risks. <i>Nutricion Hospitalaria</i> , 2013, 28 Suppl 5, 121-7.	0.2	4
444	Comparative effectiveness of a low-calorie diet combined with acupuncture, cognitive behavioral therapy, meal replacements, or exercise for obesity over different intervention periods: A systematic review and network meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
446	Signaling pathways in obesity: mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	72

#	ARTICLE	IF	CITATIONS
447	Estimating Tree-Based Dynamic Treatment Regimes Using Observational Data with Restricted Treatment Sequences. <i>Biometrics</i> , 2023, 79, 2260-2271.	0.8	2
448	Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches. <i>Nutrients</i> , 2022, 14, 4801.	1.7	5
449	8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: <i>Standards of Care in Diabetesâ€™2023</i>. <i>Diabetes Care</i> , 2023, 46, S128-S139.	4.3	83
450	Pharmacological Support for the Treatment of Obesityâ€™Present and Future. <i>Healthcare (Switzerland)</i> , 2023, 11, 433.	1.0	6
451	Insights on Dietary Polyphenols as Agents against Metabolic Disorders: Obesity as a Target Disease. <i>Antioxidants</i> , 2023, 12, 416.	2.2	21
452	Defining Predictors of Weight Loss Response to Lorcaserin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	0
453	5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators. <i>Nutrients</i> , 2023, 15, 1449.	1.7	3
455	Treatment: Lifestyle and Medication. <i>Contemporary Cardiology</i> , 2023, , 825-847.	0.0	0